| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| S9083 |
Global fee urgent care centers |
53,244 |
36,613 |
$3.24M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
9,612 |
8,499 |
$860K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
9,631 |
9,037 |
$840K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,338 |
6,731 |
$714K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
4,032 |
3,800 |
$377K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
4,517 |
2,313 |
$46K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
3,506 |
1,722 |
$40K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,487 |
755 |
$17K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
181 |
160 |
$12K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
677 |
216 |
$8K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,150 |
618 |
$7K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
207 |
173 |
$1K |
| 99051 |
|
686 |
264 |
$1K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
83 |
66 |
$375.01 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,050 |
898 |
$103.75 |
| 81003 |
|
57 |
57 |
$2.02 |
| A9150 |
Non-prescription drugs |
112 |
97 |
$0.00 |
| 87807 |
|
48 |
46 |
$0.00 |
| K1034 |
Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count |
56 |
56 |
$0.00 |